Log in

NYSE:AGEAgeX Therapeutics Stock Price, Forecast & News

-0.06 (-5.31 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $1.07
50-Day Range
MA: $0.80
52-Week Range
Now: $1.07
Volume976,185 shs
Average Volume192,652 shs
Market Capitalization$40.29 million
P/E RatioN/A
Dividend YieldN/A
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$1.73 million
Book Value($0.01) per share


Net Income$-12,150,000.00
Net Margins-658.11%


Market Cap$40.29 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.

AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions

How has AgeX Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

AgeX Therapeutics' stock was trading at $0.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGE shares have increased by 21.6% and is now trading at $1.07. View which stocks have been most impacted by Coronavirus.

When is AgeX Therapeutics' next earnings date?

AgeX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for AgeX Therapeutics.

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics (NYSE:AGE) announced its earnings results on Thursday, May, 14th. The company reported ($0.08) EPS for the quarter. The business had revenue of $0.52 million for the quarter. AgeX Therapeutics had a negative net margin of 658.11% and a negative return on equity of 334.65%. View AgeX Therapeutics' earnings history.

Has AgeX Therapeutics been receiving favorable news coverage?

News coverage about AGE stock has trended very positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AgeX Therapeutics earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAgeX Therapeutics.

Who are some of AgeX Therapeutics' key competitors?

What other stocks do shareholders of AgeX Therapeutics own?

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the following people:
  • Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
  • Dr. Michael D. West, Pres, CEO & Director (Age 65)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Nafees Naseer Malik, Chief Operating Officer
  • Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

Who are AgeX Therapeutics' major shareholders?

AgeX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.04%), State Street Corp (0.78%), Defender Capital LLC. (0.14%) and Wells Fargo & Company MN (0.12%). View institutional ownership trends for AgeX Therapeutics.

Which institutional investors are selling AgeX Therapeutics stock?

AGE stock was sold by a variety of institutional investors in the last quarter, including Defender Capital LLC., and BlackRock Inc.. View insider buying and selling activity for AgeX Therapeutics.

Which institutional investors are buying AgeX Therapeutics stock?

AGE stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, and State Street Corp. View insider buying and selling activity for AgeX Therapeutics.

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $1.07.

How big of a company is AgeX Therapeutics?

AgeX Therapeutics has a market capitalization of $40.29 million and generates $1.73 million in revenue each year.

What is AgeX Therapeutics' official website?

The official website for AgeX Therapeutics is www.agexinc.com.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The company can be reached via phone at 510-671-8370.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.